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Original Article
Association of GPX1 polymorphism,
GPX activity and prostate cancer risk
O Erdem1, A Eken1, C Akay1, Z Arsova-Sarafinovska2,
N Matevska3, L Suturkova3, K Erten4, Y O¨zgo¨k4,
A Dimovski3, A Sayal1 and A Aydın5
Abstract
Prostate cancer is the second most common cancer in men worldwide. Although the aetiology of this disease
remains largely unclear, several lines of evidence suggest that oxidative stress plays a role in prostate carcino-
genesis. The antioxidant enzyme glutathione peroxidase 1 (GPX1) is part of the enzymatic antioxidant defence,
preventing oxidative damage to DNA, proteins and lipids by detoxifying hydrogen and lipid peroxides that may
contribute to prostate cancer development. Some studies indicate an association between GPX1 Pro198Leu
polymorphism and an increased risk of cancer. The purpose of the present study was to determine the possible
association of GPX1 Pro198Leu polymorphism and erythrocyte GPX activity with the risk of developing
prostate cancer and to clarify whether erythrocyte GPX activity levels were correlated with the GPX1
Pro198Leu genotype in the Turkish population. The GPX1 Pro198Leu genotype was determined in 33 prostate
cancer patients and 91 control individuals. As evident from our results, there was no difference between
genotype and/or allele frequencies in prostate cancer patients and controls. No significant difference was found
in GPX1 genotype or allele frequency between aggressive and non-aggressive prostate cancer patients. It can
be suggested with these findings that individual susceptibility of prostate cancer may be modulated by GPX1
polymorphism, but it needs further studies.
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Introduction
Prostate cancer continues to be a major age-related
malignancy with most incidences occurring between
54 and 75 years and rapid onset after 45 years. Evi-
dence from epidemiological, experimental and clini-
cal studies suggests that prostate cancer cells are
exposed to an increased oxidative stress.1,2 Reactive
oxygen species (ROS), most notably the hydroxyl
radicals, generated endogenously by cellular metabo-
lism are known to cause oxidative DNA damage that
has been implicated in prostate carcinogenesis.3
The antioxidant enzyme glutathione peroxidase 1
(GPX1) is part of the enzymatic antioxidant defence,
preventing oxidative damage to DNA, proteins and
lipids by detoxifying hydrogen and lipid peroxides.4,5
The cytosolic form of GPX1 belongs to a family of
selenium-dependent peroxidases that include cytoso-
lic GPX,6 plasma-based GPX37 and phospholipids
hydroperoxidase GPX4.8 GPX1 knockout mice have
a normal phenotype but are highly sensitive to
oxidative stressors.9 Human GPX1 gene was found
to possess several polymorphisms. The GPX1 gene
has a GCG repeat polymorphism in exon 1, coding for
a polyalanine tract of five to seven alanine residues.
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